Cytokinetics Announces Positive Results From SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy
December 27, 2023 07:30 ET
|
Cytokinetics, Incorporated
Statistically Significant and Clinically Meaningful Increasein Primary Efficacy Endpoint at 24 Weeks of Treatment; Improvement Consistent Across All Prespecified Subgroups Statistically Significant...
Cytokinetics to Host Investor Call on December 27 to Discuss the Topline Results from SEQUOIA-HCM, the Pivotal Phase 3 Clinical Trial of Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy
December 26, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of its senior management will host an investor call at 8:30 AM...
Cytokinetics Presents Results From COURAGE-ALS at the 34th International Symposium on ALS/MND
December 07, 2023 07:30 ET
|
Cytokinetics, Incorporated
As Previously Announced, Reldesemtiv Had No Effect on the Primary Endpoint of Change from Baseline in ALSFRS-R or Key Secondary Endpoints Trial Discontinued in March 2023 Due to Futility Following...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on November 30, 2023 it granted stock options to purchase an aggregate...
Cytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MND
November 29, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five presentations at the 34th International Symposium on ALS/MND taking...
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
November 03, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on October 31, 2023 it granted stock options to purchase an aggregate of...
Cytokinetics Reports Third Quarter 2023 Financial Results
November 02, 2023 16:00 ET
|
Cytokinetics, Incorporated
On Track for Topline Results from SEQUOIA-HCM,a Pivotal Phase 3 Clinical Trial of Aficamten in Obstructive HCM,in Late December Long-Term Data from FOREST-HCM, the Open-Label Extension Study of...
Cytokinetics to Participate in Upcoming Investor Conferences
November 01, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor...
Cytokinetics to Announce Third Quarter Results on November 2, 2023
October 23, 2023 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 2, 2023 at...
Cytokinetics Provides Update on Cardiac Myosin Inhibitor Programs and Plans to Build a Specialty Cardiology Franchise at Virtual Investor & Analyst Day
October 19, 2023 07:30 ET
|
Cytokinetics, Incorporated
New Long-Term Data from FOREST-HCM, the Open-Label Extension Study of Aficamten,Show Sustained Improvements in Clinical Efficacy Endpointsand No Treatment Interruptions for Low Ejection Fraction ...